IFI35 and myeloid sarcoma: Moreover, IFP35 appears to have a more relevant involvement in Multiple Sclerosis (MS), due to the chronic inflammatory nature of the disease, and to the IFN-beta-1a usage as the first line disease modifying treatment (DMT) of this condition.